Showing 2131-2140 of 2652 results for "".
- Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunctionhttps://modernod.com/news/azura-ophthalmics-announces-positive-results-from-phase-2b-clinical-trial-of-azr-md-001-in-meibomian-gland-dysfunction/2481247/Azura Ophthalmics announced positive 3-month efficacy and safety results from its phase 2b study of AZR-MD-001 0.5% in Meibomian Gland Dysfunction (MGD). The trial met its co-primary endpoints of improvements in Meibomian Glands Yielding Liquid Secretion (MGYLS; number of open glands) and Oc
- Atsena Therapeutics Expands Leadership Team with Appointment of Lis Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officerhttps://modernod.com/news/atsena-therapeutics-expands-leadership-team-with-appointment-of-lis-leiderman-md-mba-as-chief-financial-officer-and-chief-business-officer/2481229/Atsena Therapeutics announced the appointment of Elisabeth (Lis) Leiderman, MD, MBA, as Chief Financial Officer and Chief Business Officer. Dr. Leiderman has more than 15 years of finance, business development and strategy experience in the life sciences industry, most recently with gene the
- Market Scope: Safer and More Effective Glaucoma Surgical Options Expected to Double Global Revenue by 2027https://modernod.com/news/market-scope-safer-and-more-effective-glaucoma-surgical-options-expected-to-double-global-revenue-by-2027/2481223/Nearly 48 million individuals are diagnosed with glaucoma globally, but just over a million, or 2.2 percent, will have surgery in 2022. However, safer and more effective surgical devices over the next 5 years will increase the percentage of glaucoma patients treated surgically to a projected 3.5
- BioTissue Completes Name Changehttps://modernod.com/news/biotissue-completes-name-change/2481211/BioTissue Holdings announced the completion of its name change from TissueTech. The change is part of a corporate-wide branding initiative launched earlier this year to better represent the company’s entire portfolio and pipeline of products. Pursuant to the name change, the former Tis
- Vyluma Announces Positive Results From Phase 3 CHAMP Study of NVK002 for Treatment of Myopia Progression in Childrenhttps://modernod.com/news/vyluma-announces-positive-results-from-phase-3-champ-study-of-nvk002-for-treatment-of-myopia-progression-in-children/2481205/Vyluma announced topline results from its phase 3 CHAMP (Childhood Atropine for Myopia Progression) clinical study. Analysis of this multicenter, international study, performed after 3 years of treatment and follow up, demonstrates strong safety and efficacy for NVK002 as a potential treatment fo
- Study: Digital Home Monitoring Shows Unique Predictive Value in Disease Progression for AMD Patientshttps://modernod.com/news/study-digital-home-monitoring-shows-unique-predictive-value-in-disease-progression-for-amd-patients/2481190/Notal Vision reported the publication of the second report of the "Analysis of Long-term visual Outcomes of ForeseeHome Remote Telemonitoring (ALOFT)" study results in Ophthalmology Retina. The 10-year retrospective study details the importance of digital remote monitor
- Lenstec Rebrands its Newly Approved Multifocal IOL to ClearView 3https://modernod.com/news/lenstec-rebrands-its-newly-approved-multifocal-iol-to-clearview-3/2481174/Lenstec announced that it has rebranded its new multifocal IOL, the SBL-3, to the ClearView 3 to better describe the vision patients can expect with the new IOL, according to Lenstec. The IOL was approved by the FDA in July 2022. "Since approval, the ClearView
- Tarsus Announces Transition Plans for Board of Directorshttps://modernod.com/news/tarsus-announces-transition-plans-for-board-of-directors/2481168/Tarsus Pharmaceuticals announced several expected upcoming transitions to its Board of Directors by year-end. Tarsus Co-Founder and Chairman, Michael Ackermann, PhD, plans to transition off the Board of Directors. Upon Dr. Ackermann’s planned transition, Wendy Yarno, industry veteran and cu
- Moria Expands its Footprint into Eye Surgery by Acquiring Alchimia SRLhttps://modernod.com/news/moria-expands-its-footprint-into-eye-surgery-by-acquiring-alchimia-srl/2481161/France-based Moria has announced the acquisition of Italian-based company Alchimia SRL, a manufacturer of devices for ophthalmic surgery and human tissue banking. Financial terms of the deal were not disclosed. Founded in 1993, Alchimia has 30 years of expertis
- Schwind Eye-Tech-Solutions Announces Management Changeshttps://modernod.com/news/schwind-eye-tech-solutions-announces-management-changes/2481149/Rolf Schwind, who was serving as CEO of Schwind eye-tech-solutions GmbH, has withdrawn from active leadership of the company, effective October 1, 2022, and joined the Advisory Board. In that capacity he will continue to contribute to the growth of Schwind with his more than 40 years of